Advance Access published September 16, 2004
|
|
- Amie Ashlee Smith
- 5 years ago
- Views:
Transcription
1 Advance Access published September 16, 2004 Journal of Antimicrobial Chemotherapy DOI: /jac/dkh435 JAC Post-antibiotic effect induced by an antibiotic combination: influence of mode, sequence and interval of exposure Ronald C. Li* and Mei C. Tang Department of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong Received 20 May 2004; returned 9 July 2004; revised 18 August 2004; accepted 18 August 2004 Objectives: The effects of mode, sequence and interval of antibiotic exposure on the post-antibiotic effect (PAE) induced by rifampicin and tobramycin were studied using Escherichia coli ATCC as the test organism. Methods: In triplicate, baseline PAEs were evaluated by exposing E. coli to rifampicin and tobramycin individually and simultaneously for 1 h. PAEs were further assessed in a second study, with the organism exposed first to rifampicin for 1 h, followed by a second 1 h tobramycin exposure, commencing at the beginning, middle and end of the PAE phase induced by rifampicin. The third study was similar to the above, but with the sequence of the two antibiotics reversed, i.e. tobramycin then rifampicin. Results: The PAE produced by simultaneous exposure of the combination showed an apparent additive interaction (PAE: h) when compared with the PAE of individual antibiotics (rifampicin alone: h; tobramycin alone: h). However, an antagonistic interaction was observed in the second study, with a more pronounced degree of antagonism at the beginning, dissipating towards the end of the previous rifampicin PAE (PAE at the beginning: h; the middle: h; and at the end: h). By subtracting the residual contribution from the first rifampicin exposure, the net average PAEs attributed to the second tobramycin exposure actually increased, from 20.4 to 1.7 h from the beginning to the end of the rifampicin PAE. For the third study, an additive interaction was again observed when the organism was exposed to tobramycin first (PAE at the beginning: h; the middle: h; and at the end: h). The timing of the second rifampicin exposure had no impact to the interaction; after correction, the net mean PAEs attributed to the second rifampicin exposure were maintained at 3.2, 3.2 and 3.1 h. Conclusions: The present data suggest that the expression of interaction type on PAE by an antibiotic combination was dependent on the mode, sequence and interval of exposure. The impact of these variables should not be overlooked when clinical dosing regimens are optimized. Keywords: PAE, rifampicin, tobramycin Introduction The ability of antibiotic combinations to improve clinical efficacy is based on the following premises: (1) to produce synergistic/additive antimicrobial effects, (2) to reduce the probability of emergence of bacterial resistance, or delay its formation and (3) to expand the spectrum of antibacterial activity beyond that of the individual antibiotics alone. Information in the literature pertaining to the study of antibiotic combinations mainly focuses on their bactericidal and inhibitory activities by utilizing time kill studies and MIC measurements Few studies report the effects of antibiotic combinations on the post-antibiotic effect (PAE). The design of most, if not all, of these studies required the test organism to be exposed to each antibiotic alone then to the combination simultaneously. When the combination produces a PAE similar to, longer or shorter than the sum of PAEs induced by the two antibiotics alone, the respective interaction is then categorized as additive, synergistic or antagonistic. However, such experimental design does not reflect the clinical situation, in which some antibiotic combinations are not administered simultaneously. This is particularly true when their regimens (e.g. twice a day versus three times a day) are not synchronized due to the different half-lives or their pharmacokinetic behaviours, physical incompatibility (e.g. b-lactams and aminoglycosides) or profound metabolic drug drug interactions.... *Correspondence address. Clinical and Exploratory Pharmacology, International Clinical Investigations, Sanofi-Synthelabo Research, 9 Great Valley Parkway, Malvern, PA 19355, USA. Tel: ; Fax: ; Ronald.Li@Sanofi-Synthelabo.com... Page 1 of 5 JAC q The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
2 R. C. Li and M. C. Tang When antibiotics in combination are not administered simultaneously, it is typical that one antibiotic is administered prior to the other. Therefore, optimal antimicrobial responses should also consider the sequence and interval of dosing. At the time of this study, the authors were not aware of any published reports examining the impact of sequential dosing of antibiotic combinations on PAE. To gain further insights in this area of research, tobramycin and rifampicin were utilized in this study as a test combination against a standard strain of Escherichia coli. The selection of this antibiotic combination was based on its known mechanisms of action rather than its clinical relevance; tobramycin acts primarily by disrupting protein synthesis leading to altered cell membrane permeability and cell death whereas rifampicin inhibits DNA-dependent RNA polymerase activity in susceptible cells. As a result of the distinct mechanisms of action, the likelihood of a pharmacological interaction between the two antibiotics is high. In this study, particular attention was given to the three variables, e.g. mode, sequence and interval of exposure of the two antibiotics, and the relevance of their interactions to PAE. Materials and methods Test organism Lyophilized E. coli ATCC 25922, purchased from Difco Laboratories (Detroit, MI, USA), was used. After initial isolation, an organism from a single colony was maintained on agar slants at 48C. Culture media Mueller Hinton broth supplemented with 25 mg of Ca 2+ and 12.5 mg of Mg 2+ per litre (MHB-S) was used throughout. Nutrient agar (lot 73271JE) was employed for the colony count assay via a pour plate technique. Both culture media were purchased from Difco Laboratories, Detroit, MI, USA and were sterilized per manufacturer s instructions. Antimicrobial agents Rifampicin and tobramycin were purchased from Sigma Chemical Co., St. Louis, MO, USA. Aqueous stock antibiotic solutions were prepared and stored frozen at 208C before use. MIC MICs of the two antibiotics and test organism were measured by the macrodilution technique 17 after 18 h of incubation at 378C. Bacterial culture The test organism maintained on an agar slant was transferred to 10 ml of MHB-S and incubated overnight at 378C. This overnight culture was diluted with MHB-S and further incubated for 2 3 h at 378C to enter logarithmic growth. The actively growing culture was subsequently diluted with MHB-S to achieve turbidity matching that of a 0.5 McFarland standard. PAE assessments To start the experiment, 0.1 ml of the adjusted culture at 0.5 McFarland was introduced to 9.9 ml of antibiotic-containing MHB- S to yield a total volume of 10 ml. Three sets of experiments, each in triplicate, were carried out; (1) E. coli was exposed to rifampicin and tobramycin individually and simultaneously for 1 h each, (2) the organism was first exposed to rifampicin for 1 h, followed by exposure for 1 h to tobramycin, at the beginning (T0; immediately after antibiotic removal of the first rifampicin exposure), middle (T1 = 2 h) and end (T2 = 4 h) of the first PAE induced by rifampicin and (3) the studies described in (2) were repeated, but with the sequence of the two antibiotics reversed, i.e. tobramycin, then rifampicin, with T0 also started immediately after removal of the first tobramycin exposure, and at the middle (T1 = 1 h) and end (T2 = 2 h) of the first PAE induced by tobramycin. With the anticipation of variability in the PAE measurements, the above time schedules would conform to the intended study conditions, i.e. exposure of the second antibiotic at the beginning, middle and end of the PAE of the first exposure. At the end of every 1 h exposure, the antibiotic(s) was removed by washing three times using sterile 0.9% saline and centrifugation at 1200 g for 10 min. For all studies, the concentrations of rifampicin and tobramycin were 25 mg/l ( MIC) and 2 mg/l (1 MIC), respectively. These concentrations were established in our preliminary studies to limit the possibility of the viable bacterial densities in samples falling below the 200 cfu/ml limit of quantification over the entire study period for all conditions. Throughout the experiments, cultures were kept at 378C using a calibrated water bath. Samples (0.1 ml) were withdrawn from the test culture hourly (up to 12 h) and submitted to the pour plate assay until steady growth was observed after removal of the last antibiotic exposure. PAE was determined as the difference between the time required for the viable count in the test culture to increase by one log unit immediately after antibiotic removal and the time required after the same procedure for the control culture. To avoid overgrowth of the control culture, dilution ( fold) using pre-warmed MHB-S was performed at the same time points as scheduled antibiotic exposures during the study. For clarity, data pertaining to the control cultures (all in simple logarithmic growth) are not shown in the Figures described in the Results section. Data interpretation Interpretation of the interaction expressed by the combination was based on the comparison of PAE ascribed to the antibiotic used in the second exposure and the PAE of that antibiotic alone. The combination was considered to be additive, antagonistic and synergistic when the former PAE was similar to, shorter and longer than the latter, respectively. Results MICs The MICs of rifampicin and tobramycin were 8 16 and 2 mg/l, respectively. PAE Following 1 h of antibiotic exposure, the mean (±S.D.) PAE estimates were 1.5 ± 0.1 h for tobramycin alone and 3.0 ± 0.1 h for rifampicin alone. Simultaneous exposure to both antibiotics for 1 h resulted in a PAE of 5.0 ± 0.3 h. Figure 1 shows the changes in bacterial density over time under the three exposure conditions. The combination would, therefore, be considered additive. Both the PAE and extent of bacterial killing were greatest when the organism was exposed to the combination in comparison to the antibiotics alone. In addition, the extent of bacterial density reduction produced by the combination Page 2 of 5
3 Antibiotic combination and PAE Figure 1. The changes in mean (±S.D.) bacterial density over time showing the extent of viable count reduction and PAE (or growth suppression) after E. coli was submitted to 1 h of exposure to tobramycin alone (T), rifampicin alone (R) and tobramycin and rifampicin simultaneously (T + R). Note: timings of the antibiotic(s) exposure and removal are indicated by vertical and horizontal arrows, respectively. immediately before antibiotic removal was approximately the sum of those by the two antibiotics alone. In the second set of experiments, when the organism was sequentially exposed to rifampicin then tobramycin, mean (S.D.) PAEs for tobramycin were 2.6 ± 0.3, 1.5 ± 0.2 and 1.7 ± 0.3 h when it was introduced at the beginning, middle and end of the PAE of the preceding rifampicin exposure. Apparently, the PAE of tobramycin was shorter when its exposure was further from the PAE of the first rifampicin exposure. However, these PAE values were not only reflective of those from the second tobramycin exposure, but also the residual PAE from the first rifampicin exposure. To generate the net apparent PAE produced by the second tobramycin exposure, the residual PAE from the first rifampicin exposure needed to be subtracted. To accomplish this, the time difference between the removal of the first rifampicin exposure and the start of the second tobramycin exposure was obtained, e.g. T0 T0, T1 T0. The residual PAE of the first rifampicin exposure was then estimated by subtracting the above time difference from the PAE of rifampicin alone observed in the first study. Taking the tobramycin exposure in the middle of the rifampicin PAE as an example, the residual PAE was [PAE rifampicin alone (T1 T0)] or [3.0 h (2.0 h 0.0 h)] = 1 h, whereas the net PAE was equal to actual PAE measured residual PAE, i.e. 1.5 h 1 h = 0.5 h. The residual PAE was zero hour for the tobramycin exposure at the end of the rifampicin PAE. Therefore, subsequent to the removal of the residual rifampicin PAE from the actual PAE measured for the second tobramycin exposure, the respective net PAEs induced by the tobramycin were thus estimated to be, on average, 0.4, 0.5 and 1.7 h under the three exposure conditions. These estimates, thus, suggest that tobramycin failed to induce a PAE of its own when it was introduced at the beginning and during the PAE phase of the previous rifampicin exposure. By definition, antagonism was expressed by the two antibiotics when the PAE of the second tobramycin exposure was less than its own PAE alone, i.e. 1.5 h. Furthermore, the net PAE for the second tobramycin exposure increased from 0.4 to 1.7 h when it was moved from the beginning to the end of the first rifampicin PAE, thereby indicating a higher degree of antagonism at an early PAE phase of rifampicin. The different patterns of viable bacterial density versus time curves are shown in Figure 2. As the PAE of the first rifampicin exposure dissipated, tobramycin exposure towards the end showed more extensive bacterial killing, suggesting that the organism had regained its susceptibility to tobramycin. When the sequence of the two antibiotics was reversed, i.e. tobramycin/rifampicin, the respective mean (S.D.) estimates of PAE for rifampicin were 4.7 ± 0.4, 3.7 ± 0.7 and 3.1 ± 0.4 h, with the rifampicin exposure scheduled at the beginning, middle and end of the PAE induced previously by tobramycin. The net PAEs produced by the second rifampicin exposure were estimated to be 3.2, 3.2 and 3.1 h under the respective conditions. Since these PAE estimates were in line with that of rifampicin alone observed in the first set of experiments, the interaction expressed by the tobramycin/rifampicin exposure could be considered additive. Figure 3 shows the bacterial density versus time profiles under the above study conditions. From the Figure, two observations are noteworthy, (1) regardless of the timing of the second rifampicin exposure, the profiles converged at >9 h and (2) the drop in bacterial count immediately after the second rifampicin exposure was similar in terms of both extent and rate and was independent of the timing of the second rifampicin exposure. This suggests the preservation of its antimicrobial effect during the PAE of tobramycin. Figure 2. The changes in mean (±S.D.) bacterial density over time following the exposure of E. coli to rifampicin (R) first for 1 h, then another 1 h of tobramycin (T) at the beginning [R!T(B)], middle [R! T(M)] and end [R! T(E)] of rifampicin PAE. Note: timing of the antibiotic exposure and antibiotic removal are indicated by vertical and horizontal arrows vertical and horizontal arrows with matching shading patterns, respectively. Except for the first rifampicin exposure (arrows not shaded), the addition and removal of the second tobramycin exposure for each of the three conditions is labelled using a separate pattern of shading. Page 3 of 5
4 R. C. Li and M. C. Tang Figure 3. The changes in mean (±S.D.) bacterial density over time following the exposure of E. coli to tobramycin (T) first for 1 h, then another 1 h of rifampicin (R) at the beginning [T!R(B)], middle [T! R(M)] and end [T! R! (E)] of tobramycin PAE. For all three conditions, a parallel decline in bacterial counts following the addition of rifampicin was observed. Note: timing of the antibiotic exposure and antibiotic removal is indicated by vertical and horizontal arrows, respectively. Except for the first tobramycin exposure (arrows not shaded), addition and removal of the second rifampicin exposure for each of the three conditions is labelled using a separate pattern of shading. Discussion PAE has been extensively studied for single antibiotics; however, the study of antibiotic combinations has received much less attention. One of the reasons might relate to the constraint on the study design; the limited studies focusing on combinations mostly adopted a simultaneous exposure design in which the test organism is exposed to the two antibiotics at the same time. Such design sharply contrasts with the actual clinical situation in which individual antibiotics in a combination can be administered in a sequential manner. The effects of sequential dosing on the pharmacodynamic behaviour of the two study antibiotics have been demonstrated in this study. As the present PAE data reveal, the conclusion on the interaction type can vary depending on the experimental conditions for the same pair of antibiotics. When the test organism was exposed to the test combination simultaneously, the interaction appeared to be additive. However, exposure first to rifampicin antagonized the PAE expressed by the second (tobramycin) exposure, and such antagonism was time-dependent during the PAE of rifampicin. On the other hand, when the organism was exposed first to tobramycin, the second (rifampicin) did not elicit similar antagonism during the PAE of tobramycin, but rather an additive interaction with no timedependency. In terms of bacterial count, simultaneous exposure to the antibiotic combination produced the most extensive reduction as compared with each antibiotic alone. The extent of reduction, similar to PAE, appeared to be additive in nature (Figure 1). However, when rifampicin was applied first, the bactericidal effect exhibited by the tobramycin (applied second) increased along with a lower degree of antagonism expressed on PAE when it was introduced towards the end of the rifampicin PAE (Figure 2). In the third set of experiments, the similar and parallel reduction in bacterial count produced by the second rifampicin exposures was consistent with the additive effect observed on PAE when exposure to tobramycin was first (Figure 3). Interpretation of these data requires a broader understanding of the pharmacological activities of the two antibiotics. Rifampicin and tobramycin act on different bacterial targets; however, the former exhibits a relatively strong bacteriostatic effect against the test organism, whereas the latter is more bactericidal. Previous studies showed that bacteriostatic agents antagonize both bactericidal activity and the PAE of bactericidal agents. 18,19 Current data from the second set of studies point in the same direction, i.e. antagonism was observed when exposure to rifampicin preceded that to tobramycin, and it was not apparent when the sequence of exposure was reversed or exposure to the two antibiotics was simultaneous. In regard to the timing of the second antibiotic exposure, the complete pharmacodynamic profile has to be considered. Data showing the longest delay in bacterial regrowth from each of the three sets of experiments are presented in Figure 4. Although the test organism received a total of 1 h of rifampicin exposure plus 1 h of tobramycin exposure in all cases, the sequence of rifampicin/tobramycin (tobramycin exposure at the end of the rifampicin PAE) delayed bacterial regrowth for the longest time, whereas the delay was shortest when exposure was simultaneous. This suggests that the former was pharmacodynamically the most attractive. In terms of the extent of bacterial density reduction over the study period, the same conclusion can be Figure 4. The composite plot of mean (±S.D.) bacterial density over time for conditions showing the longest PAE observed in the three sets of experiments; tobramycin together with rifampicin for 1 h (T + R), 1 h of rifampicin then 1 h of tobramycin at the end of the rifampicin PAE [R!T(E)], and 1 h of tobramycin then 1 h of rifampicin at the beginning of the tobramycin PAE [T! R(B)]. The different pharmacodynamic profiles show a clear impact of the mode, sequence and interval of antibiotic exposure. Note: arrows identical to those in Figures 1 3 are used to label antibiotic addition and removal. Page 4 of 5
5 Antibiotic combination and PAE drawn. The positive relationship observed between the extent of bacterial killing and the length of PAE is in good agreement with the data we reported previously. 20 In summary, present data support the need to consider the mode, sequence as well as interval of exposure when an antibiotic combination is used because all these factors contribute to the two pharmacodynamic attributes studied, i.e. bactericidal activity and PAE. More importantly, these factors should not be overlooked when antibiotic combinations are utilized in the clinic. References 1. Sader, H. S., Huynh, H. K. & Jones, R. N. (2003). Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and b-lactams tested against gram-negative bacilli. Diagnostic Microbiology and Infectious Disease 47, Mandal, S., Mandal, M. D. & Pal, N. K. (2003). Combination effect of ciprofloxacin and gentamicin against clinical isolates of Salmonella enterica serovar Typhi with reduced susceptibility to ciprofloxacin. Japanese Journal of Infectious Diseases 56, Sweeney, M. T. & Zurenko, G. E. (2003). In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms. Antimicrobial Agents and Chemotherapy 47, Critchley, I. A., Sahm, D. F., Kelly, L. J. et al. (2003). In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli. Chemotherapy 49, Jung, R., Husain, M., Choi, M. K. et al. (2004). Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates. Antimicrobial Agents and Chemotherapy 48, Erdem, I., Kucukercan, M. & Ceran, N. (2003). In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Chemotherapy 49, Dawis, M. A., Isenberg, H. D., France, K. A. et al. (2003). In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. Journal of Antimicrobial Chemotherapy 51, Jacqueline, C., Caillon, J., Le Mabecque, V. et al. (2003). In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. Journal of Antimicrobial Chemotherapy 51, Gunderson, B. W., Ibrahim, K. H., Hovde, L. B. et al. (2003). Synergistic activity of colistin and ceftazidime against multiantibioticresistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 47, Fish, D. N., Choi, M. K. & Jung, R. (2002). Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. Journal of Antimicrobial Chemotherapy 50, Kato, K., Iwai, S., Sato, T. et al. (2002). In-vitro activity of ciprofloxacin combined with flomoxef against Bacteroides fragilis, compared with that of ciprofloxacin combined with clindamycin. Journal of Infection and Chemotherapy 8, Hostacka, A. (1997). Comparison of postantibiotic effects of imipenem and netilmicin alone and in combination against Pseudomonas aeruginosa. Arzneimittelforschung 47, Sood, P., Mandal, A. & Mishra, B. (2000). Postantibiotic effect of a combination of antimicrobial agents on Pseudomonas aeruginosa. Chemotherapy 46, Chan, C. Y., Au-Yeang, C., Yew, W. W. et al. (2001). Postantibiotic effects of antituberculosis agents alone and in combination. Antimicrobial Agents and Chemotherapy 45, Nyhlen, A., Ljungberg, B., Nilsson-Ehle, I. et al. (2002). Postantibiotic effect of meropenem and ciprofloxacin in the presence of 5-fluorouracil. Chemotherapy 48, Gudmundsson, S., Erlendsdottir, H., Gottfredsson, M. et al. (1990). The postantibiotic effect induced by antimicrobial combinations. Scandinavian Journal of Infectious Diseases Supplementum 74, National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Third Edition: Approved Standard M7-A3. NCCLS, Villanova, PA, USA. 18. Gudmundsson, S., Vogelman, B. & Craig, W. A. (1994). Decreased bactericidal activity during the period of the postantibiotic effect. Journal of Antimicrobial Chemotherapy 34, Li, R. C., Schentag, J. J. & Nix, D. E. (1993). The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. Antimicrobial Agents Chemotherapy 37, Li, R. C., Lee, S. W. & Kong, C. H. (1997). Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action. Journal of Antimicrobial Chemotherapy 40, Page 5 of 5
Tel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationInfluence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationThe Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University
The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3 Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University Tae-yoon Choi ABSTRACT BACKGROUND: The use of disinfectants
More informationReceived 17 December 2003; accepted 22 December 2003
Journal of Antimicrobial Chemotherapy (2004) 53, 609 615 DOI: 10.1093/jac/dkh130 Advance Access publication 3 March 2004 In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines,
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More information6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS
6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationIn vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms
Advance Access published April 14, 2003 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkg238 In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationPostantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method
Journal of Antimicrobial Chemotherapy (1988) 22, 23-33 Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method Barforo Isaksson'*, Lennart Nibson*, Rolf Mailer' and
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationAlasdair P. MacGowan*, Mandy Wootton and H. Alan Holt
Journal of Antimicrobial Chemotherapy (1999) 43, 345 349 JAC The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationBrief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents
Journal of Antimicrobial Chemotherapy (5) 35, -5 Brief reports Heat stability of the antimicrobial activity of sixty-two antibacterial agents Walter H. Traub and Birgit Leonhard Institut fur Medizinische
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationAntibacterial activity of Stephania suberosa extract against methicillin-resistant Staphylococcus aureus
B-O-021 Antibacterial activity of Stephania suberosa extract against methicillin-resistant Staphylococcus aureus Nongluk Autarkool *a, Yothin Teethaisong a, Sajeera Kupittayanant b, Griangsak Eumkeb a
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationImpact of Spores on the Comparative Efficacies of Five Antibiotics. Pharmacodynamic Model
AAC Accepts, published online ahead of print on 12 December 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01109-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationANTIMICROBIAL TESTING. with ALKA VITA (ALKAHYDROXY ) ESCHERICHIA COLI STAPHYLOCOCCUS AUREUS (MRSA) PSEUDOMONA AERUGINOSA ENTEROBACTER CLOACAE
ANTIMICROBIAL TESTING with ALKA VITA (ALKAHYDROXY ) on ESCHERICHIA COLI STAPHYLOCOCCUS AUREUS (MRSA) PSEUDOMONA AERUGINOSA ENTEROBACTER CLOACAE FINAL RESULTS OF ANTIBACTERIAL TESTS IN VITRO WITH THE PRODUCT
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationIN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA
IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA YONGYUTH JITTAROPAS NAOTO 1), RIKITOMI 2), and Kaizo MATSUMOTO 2) 1) Department of
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationIn Vitro Activity of Netilmicin, Gentamicin, and Amikacin
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin
More informationAntibacterial Agents & Conditions. Stijn van der Veen
Antibacterial Agents & Conditions Stijn van der Veen Antibacterial agents & conditions Antibacterial agents Disinfectants: Non-selective antimicrobial substances that kill a wide range of bacteria. Only
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationAntibacterial susceptibility testing
Antibiotics: Antil susceptibility testing are natural chemical substances produced by certain groups of microorganisms (fungi, ) that inhibit the growth of or kill the other that cause infection. Several
More informationPrinciples and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013
Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationMichael T. Sweeney* and Gary E. Zurenko. Infectious Diseases Biology, Pharmacia Corporation, Kalamazoo, Michigan 49007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2003, p. 1902 1906 Vol. 47, No. 6 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.6.1902 1906.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationReceived 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationIn vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Journal of Antimicrobial Chemotherapy Advance Access published February 8, 2007 Journal of Antimicrobial Chemotherapy doi:.93/jac/dkl52 In vitro pharmacodynamics of colistin against Acinetobacter baumannii
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationAntibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
More informationEvaluation of the AutoMicrobic System for Susceptibility Testing of Aminoglycosides and Gram-Negative Bacilli
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1987, p. 546-550 0095-1137/87/030546-05$02.00/0 Copyright C 1987, American Society for Microbiology Vol. 25, No. 3 Evaluation of the AutoMicrobic System for Susceptibility
More informationExtremely Drug-resistant organisms: Synergy Testing
Extremely Drug-resistant organisms: Synergy Testing Background Acinetobacter baumannii& Pseudomonas aeruginosa Emerging Gram-negative bacilli Part of the ESKAPE group of organisms 1 Enterococcus faecium
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationDetermination of antibiotic sensitivities by the
Journal of Clinical Pathology, 1978, 31, 531-535 Determination of antibiotic sensitivities by the Sensititre system IAN PHILLIPS, CHRISTINE WARREN, AND PAMELA M. WATERWORTH From the Department of Microbiology,
More informationRecommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee
VICH GL27 (ANTIMICROBIAL RESISTANCE: PRE-APPROVAL) December 2003 For implementation at Step 7 - Final GUIDANCE ON PRE-APPROVAL INFORMATION FOR REGISTRATION OF NEW VETERINARY MEDICINAL PRODUCTS FOR FOOD
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationIsolation of antibiotic producing Actinomycetes from soil of Kathmandu valley and assessment of their antimicrobial activities
International Journal of Microbiology and Allied Sciences (IJOMAS) ISSN: 2382-5537 May 2016, 2(4):22-26 IJOMAS, 2016 Research Article Page: 22-26 Isolation of antibiotic producing Actinomycetes from soil
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationReceived 27 August 2002; returned 26 November 2002; revised 8 January 2003; accepted 11 January 2003
Journal of Antimicrobial Chemotherapy (2003) 51, 905 911 DOI: 10.1093/jac/dkg152 Advance Access publication 13 March 2003 AUC 0 t /MIC is a continuous index of fluoroquinolone exposure and predictive of
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More information